Immunotech Biopharm logo

Immunotech Biopharm(SEHK) 6978

Market CapHK$247.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-97%
5 Year-98%
1 Year-90%
1 Month-10%
HK$0.40
-1.25%
-0.01Today
Immunotech Biopharm last closing stock price
MetricPriceDate
Last closeHKD 0.402026-10-14
Immunotech Biopharm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.82%HKD 0.422026-10-07
1 month-10.23%HKD 0.442026-09-14
3 month-25.47%HKD 0.532026-07-16
Year to date-86.52%HKD 2.932025-12-31
1 year-90.37%HKD 4.102025-10-14
3 year-90.37%HKD 4.102023-10-13
5 year-97.52%HKD 15.922021-10-15
Since inception-97.19%HKD 14.232020-07-10

Immunotech Biopharm Financials at a Glance

Market Cap

HK$247.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥0.00

Net Income (TTM)

-CN¥392.39M

EPS (TTM)

-HK$0.34

P/E Ratio

-1.19

Dividend

HK$0.00

Beta (Volatility)

0.03 (Low)

Price

HK$0.40

Volume

58,200

Open

HK$0.40

Previous Close

HK$0.40

Daily Range

HK$0.39 - HK$0.40

52-Week Range

HK$0.33 - HK$4.30

Estimated Earnings Date

Mar 19, 2027

6978 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunotech Biopharm

Immunotech Biopharm Ltd is a biopharmaceutical company focused on cellular immunotherapy, primarily targeting various cancers in China. The firm is advancing its flagship product, EAL, through clinical trials while exploring additional therapies for multiple cancer types.

Products and Services
  • EAL: A multi-target cellular immunotherapy in Phase II trials for liver cancer
  • 6B11-OCIK injection: Currently in Phase I trials for ovarian cancer
  • CAR-T-19 injection: Targeting B-cell acute lymphoblastic leukaemia
Growth Outlook
  • Ongoing Phase II trials for EAL may lead to market introduction
  • Expansion into lung cancer and glioma treatments is underway
  • Strong pipeline with multiple therapies in various stages of development
Financial Highlights
  • Recent quarterly net income reported at -68.9 million CNY
  • Trailing twelve months (TTM) revenue remains at zero, reflecting early-stage development
  • Current ratio at 0.22 indicates potential liquidity challenges
Immunotech Biopharm Ltd operates in a highly competitive biotechnology sector, focusing on innovative cancer therapies. The company’s flagship product, EAL, is undergoing critical clinical trials, which could significantly impact its market position. The firm is also exploring additional treatment options, enhancing its growth potential. However, financial metrics indicate challenges, including a negative net income and a low current ratio, suggesting the need for careful monitoring of liquidity and operational efficiency. Investors may find the company's commitment to advancing cancer therapies compelling, despite the inherent risks associated with early-stage biopharmaceutical ventures.
AI Generated • Oct 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

183

CEO

Jian Zhang

Headquarters

Beijing, BE, CN

6978 Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

345.69%

Return on Capital

-36.54%

Return on Assets

-35.20%

Earnings Yield

-84.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$247.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

617.50M

Volume

58.20K

Avg. Volume

177.31K

Financials (TTM)

Gross Profit

-CN¥49.84M

Operating Income

-CN¥326.74M

EBITDA

-CN¥219.38M

Operating Cash Flow

-CN¥218.53M

Capital Expenditure

-CN¥32.63M

Free Cash Flow

-CN¥251.16M

Cash & ST Invst.

CN¥65.93M

Total Debt

CN¥402.12M

Immunotech Biopharm Performance Analysis

Immunotech Biopharm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 0N/A
20232023-12-31CNY 0N/A
20242024-12-31CNY 0N/A
20252025-12-31CNY 0N/A
Immunotech Biopharm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A
Immunotech Biopharm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.66-13.3%
20232023-12-31CNY -0.660.0%
20242024-12-31CNY -0.36-45.2%
20252025-12-31CNY -0.4625.9%
Immunotech Biopharm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30-38.9%
Q42025-12-3132.0%
Q22026-06-3035.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥0.00

N/A

Gross Profit

-CN¥23.76M

N/A

Gross Margin

0.00%

N/A

Market Cap

HK$247.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.31M

N/A

Employees

189

N/A

Net Income

-CN¥68.90M

+25.5%

EBITDA

-CN¥45.60M

+46.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥65.93M

-54.6%

Total Debt

CN¥402.12M

-1.8%

Accounts Receivable

CN¥269.95K

N/A

Inventory

CN¥5.92M

-13.6%

Long Term Debt

CN¥71.43M

-26.5%

Short Term Debt

CN¥330.67M

+6.0%

Return on Assets

-35.20%

N/A

Return on Invested Capital

-4.94%

N/A

Free Cash Flow

-CN¥75.43M

+23.9%

Operating Cash Flow

-CN¥65.21M

+18.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.11-5.29%
CRWVCoreWeave
$66.45-14.59%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$41.49+10.86%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$114.10-10.56%

Questions About 6978

What is the current price of Immunotech Biopharm?

Immunotech Biopharm is trading at HK$0.40 per share.

What is the 52-week range for Immunotech Biopharm?

Over the past 52 weeks, Immunotech Biopharm has traded between HK$0.33 and HK$4.30.

How much debt does Immunotech Biopharm have?

As of the most recent reporting period, Immunotech Biopharm reported total debt of CN¥490.37M.

How much cash does Immunotech Biopharm have on hand?

Immunotech Biopharm reported CN¥60.66M in cash and cash equivalents in its most recent financial results.

What is Immunotech Biopharm’s dividend yield?

Immunotech Biopharm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services